AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
- Details
Results from a phase 3 trial shows vision restoration in patients with RPE65-mediated inherited retinal dystrophies.
Read more: Gene therapy for retinal dystrophies meets endpoint
- Details
The 2-piece system allows for easy exchange of the optic to correct residual refractive error during surgery or 3 months postop.
- Details
InnFocus secured $32.8 million in Series C financing to fund the study of its MicroShunt glaucoma drainage system.
- Details
A 60-year-old woman is the first of 10 patients in the UK to receive embryonic stem cell therapy for AMD.
- Details
AngioPlex OCT angiography, which can image the retina without injecting fluorescence, has received clearance from the U.S. FDA.
- Details
FDA officials recently announced the availability of draft guidance on the nonproprietary naming of biological products, calling it a key issue for ensuring their safety and promoting their acceptance.
Read more: FDA issues draft guidance on nonproprietary naming of biologics, biosimilars